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Abstract
Background: Schistosoma haematobium is a waterborne parasite that may cause female genital schistosomiasis (FGS),
characterized by genital mucosal lesions. There is clinical and epidemiological evidence for a relationship between FGS and
HIV. We investigated the impact of FGS on HIV target cell density and expression of the HIV co-receptor CCR5 in blood and
cervical cytobrush samples. Furthermore we evaluated the effect of anti-schistosomal treatment on these cell populations.
Design: The study followed a case-control design with post treatment follow-up, nested in an on-going field study on FGS.
Methods: Blood and cervical cytobrush samples were collected from FGS negative and positive women for flow cytometry
analyses. Urine samples were investigated for schistosome ova by microscopy and polymerase chain reaction (PCR).
Results: FGS was associated with a higher frequency of CD14+ cells (monocytes) in blood (11.5% in FGS+ vs. 2.2% in FGS-,
p = 0.042). Frequencies of CD4+ cells expressing CCR5 were higher in blood samples from FGS+ than from FGS- women
(4.7% vs. 1.5%, p= 0.018). The CD14+ cell population decreased significantly in both compartments after anti-schistosomal
treatment (p = 0.043). Although the frequency of CD4+ cells did not change after treatment, frequencies of CCR5 expression
by CD4+ cells decreased significantly in both compartments (from 3.4% to 0.5% in blood, p = 0.036; and from 42.4% to 5.6%
in genital samples, p = 0.025).
Conclusions: The results support the hypothesis that FGS may increase the risk of HIV acquisition, not only through damage
of the mucosal epithelial barrier, but also by affecting HIV target cell populations, and that anti-schistosomal treatment can
modify this.
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Introduction
Heterosexual intercourse is the most frequent mode of
transmitting Human Immunodeficiency Virus (HIV), infecting
women by entry into HIV target cells in the genital mucosa [1,2].
Sexually transmitted infections (STIs) have been hypothesized to
increase HIV susceptibility by causing breaches in the genital
epithelium, by increasing the number of HIV target cells and by
immune activation in the genital mucosa [3,4]. The mechanisms
of HIV transmission to target cells and the immune responses in
the genital tract are still poorly understood [5]. Monocytes and T-
cells expressing the CD4 receptor and the chemokine receptor
CCR5 can be infected with HIV [6–8]. Factors that influence the
number of HIV target cells and their receptors may increase the
risk of HIV transmission at the site of exposure [4,9–12]. Recently,
several studies have found that women from sub-Saharan Africa
have increased systemic and genital immune activation compared
to women from Europe and North America [13–16]. It has been
hypothesized that this may be related to regional diseases such as
schistosomiasis [13–16].
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Schistosoma (S.) haematobium is a poverty-related, waterborne
parasite which coexists with HIV in many countries [15]. Of the
parasitic diseases, only malaria has a larger socioeconomic and
public health impact than schistosomiasis [17]. Women with
schistosomiasis may have lesions in the genital tract, a condition
referred to as female genital schistosomiasis (FGS, Figure 1), which
has been hypothesized to be a co-factor for HIV transmission
similar to STIs [18]. Histopathological studies have demonstrated
that the tissue surrounding the schistosomal ova is more densely
vascularized and have more CD4+ T-cells than healthy cervical
tissue [19,20]. Cross-sectional studies have found a three- to four-
fold increased odds of having HIV in women with urogenital
schistosomiasis [21,22]. A recent study showed a similar tendency
in individuals infected with S. mansoni [23]. Furthermore, the
intestinal mucosa of macaques with S. mansoni infection has been
shown to be 17-fold more susceptible to HIV infection than
healthy controls [24,25]. Praziquantel is the recommended
treatment for schistosomiasis, however, the effect on genital lesions
is still unknown [26].
In humans, little is known about the effect of genital parasite
infections on the susceptibility to HIV [13]. To our knowledge, no
studies have explored the presence of HIV receptors and co-
receptors in the genital and blood compartments in young women
with FGS. In this in-vivo study, we investigated the influence of




The women were part of a cohort of high-school students
included in a prospective intervention study in rural KwaZulu-
Natal, South Africa. The area is endemic for S. haematobium and the
infection is prevalent from an early age [27]. Frequent contact
with fresh water bodies is common in the area, both for
recreational purposes and chores such as laundry [28]. S. mansoni
is not endemic in the district (in a subsample of the main cohort,
no S. mansoni ova were found in 853 stool samples. One sample per
person was examined microscopically by the Kato-Katz method,
unpublished).
We recruited FGS+ and FGS- young females in a nested case-
control study. Sexually active females from the highest grades of
high school were included. The samples were collected from May
to June 2011 and January to February 2012. Baseline enrolment
was done in two rounds with an interval of approximately 8
months. In total, 14 FGS+ women were enrolled in the first round
and post-treatment samples collected in January and February
2012. All visits followed the same protocol. Women with FGS
were treated with praziquantel (40 mg/kg) at baseline.
FGS+ cases were included based exclusively on findings of
pathognomonic sandy patches by photocolposcopic investigation
[18] (Figure 1).Women were excluded if they reported having
HIV, were menstruating or had visible signs or symptoms of an
STI. For comparison, control samples were collected consecutively
from women enrolled in the main study without sandy patches and
with no finding of schistosome eggs by microscopy of urine. PCR
detection of schistosome DNA was run on urine and cervicovag-
inal lavage (CVL), and clinically negative controls who had a
positive PCR result were excluded (Figure 2). Women who were
found to be HIV seropositive, or had cervical sampling incorrectly
done, were excluded.
Ethics
Research ethical committees in South Africa and Norway
approved the study (Biomedical Research Ethics Committee
(BREC), University of KwaZulu-Natal (Ref BF029/07), Kwa-
Zulu-Natal Department of Health, (Reference HRKM010-08) and
the Regional Committee for Medical and Health Research Ethics
(REC), South Eastern Norway (Ref 469-07066a1.2007.535)).
Furthermore, the Departments of Health and Education in Ugu
District, KwaZulu-Natal gave permissions for this study. All
participants signed individual, written informed consents. The
ethical committees, BREC and REC, were aware that 16 and 17
year olds were participating in the study and specifically approved
the consent procedure (independent minor consent, no parental
consent). According to South African legislation, persons over the
age of 12 may consent independently to participate in research.
STI treatment was offered to participants with clinical signs and
symptoms, and their partners in accordance with the South
African syndromic treatment protocol [29]. They were also treated
at follow-up if the woman tested positive on laboratory analyses.
Anti-schistosomal treatment was offered to all as part of a mass
drug administration campaign. Voluntary HIV testing and follow-
up was done in accordance with South African guidelines with
pre- and post-test counseling. HIV+ women were referred to local
clinics for follow-up and treatment. South Africa provides
universal access to antiretroviral treatment.
Clinical investigation and specimen collection
The gynecological examinations were performed by two trained
female medical doctors (EK, KL). All cases had extensive,
characteristic sandy patches with deep and/or superficial grains
visible in the cervical mucosa. Colposcopic examination was done
of the entire cervicovaginal surface (Olympus OCS 500 Photo-
colposcope with a mounted Olympus E420 10 megapixels (Mpx)
or a Leisegang colposcope with a Canon EOS 40D 10 Mpx). For
quality control purposes, lesion sizes and localization were
documented. Quality control was done by clinicians with extensive
experience in FGS and gynecology (EFK, MO).
The investigation commenced by collecting cervical cells using
an endocervical cytobrush (EndoCervex-brush, Rovers, Oss, The
Netherlands) as previously described [30–33]. Briefly, the brush
was rotated 360u in the cervical os. After collection, the cytobrush
samples were placed in a transport medium (R10 made of RPMI
supplemented with 10% foetal calf serum (FCS), HEPES buffer, L-
glutamine, streptomycin, and penicillin) at room temperature for
Figure 1. Colposcopic image of cervix with female genital
schistosomiasis. The image shows sandy patches appearing as grains
(arrows point to some examples) and contact bleeding.
doi:10.1371/journal.pone.0098593.g001
HIV Target Cells in Female Genital Schistosomiasis
PLOS ONE | www.plosone.org 2 June 2014 | Volume 9 | Issue 6 | e98593
transport to the laboratory. CVL samples were then collected by
flushing 10 mL of sterile saline on the cervical surface four times
before drawing it back into a syringe and depositing it into tubes
for frozen storage. Urine was collected from each woman, between
10 am and 2 pm. In addition, whole blood (30 mL) was collected
into sterile acid-citrate-dextrose anti-coagulated Vacutainer tubes
(Becton, Dickinson and Company (BD), Franklin Lakes, NJ, US).
Blood and cervical cytobrush samples were transported to the
laboratory within four hours of collection.
STI and schistosomiasis testing
Baseline CVL samples were subsequently analyzed by strand
displacement assay (SDA) for Neisseria gonorrhea (ProbeTec CT/
GT, BD) and Chlamydia trachomatis (ProbeTec CT/GC, BD). PCR
was used to detect Trichomonas (T.) vaginalis (in-house PCR,
Laboratory of Infection, Prevention and Control (IPC), University
of KwaZulu-Natal (UKZN), Durban, South Africa) and Herpes
simplex virus (in-house PCR, IPC). Syphilis was detected in thawed
serum samples using Macro Vue test 110/112 for Rapid plasma
reagin (RPR), (BD), and Immutrep for Treponema pallidum
hemagglutination assay (TPHA; Omega diagnostics Group PLC,
Alva, Scotland, UK). HIV testing was done using Bioline Rapid
Test HIV, (NJ, US) and confirmatory Sensa Tri-Line HIV Test
Kit (Pantech, Durban, South Africa).
CVL and urine samples were analysed using an in-house real-
time PCR technique for detection of schistosome DNA (Leiden
University Medical Centre, Leiden, Netherlands)[34].
Microscopy was performed by adding merthiolate-formalin
solution (2%) to ten mL of urine, centrifuging and depositing the
whole pellet on one or more glass slides. Schistosome ova in urine
were counted and a positive diagnosis was recorded if at least one
ovum was seen.
Flow cytometry on cervical cytobrush and peripheral
blood mononuclear cells
In the laboratory, the cervical cytobrush samples were processed
for genital tract cells and blood for peripheral blood mononuclear
cells (PBMCs). The cytobrushes were flushed 30 times with R10 in
the tube using a pipette. The suspension was then transferred to a
new tube and centrifuged at 2100 rpm for 3 minutes. After a
second washing, the pellet was resuspended in 2 mL phosphate
buffered saline (PBS). In addition, fresh PBMCs were isolated
using Ficoll-Hypaque density gradient centrifugation (Histopaque-
1077, Sigma-Aldrich, St. Louis, MO, US). All of the cervical
cytobrush cells and 26106 PBMCs were stained for 20 minutes in
the dark, first with ViVid LIVE/DEAD (Invitrogen, NY, US),
then with a panel including CD8 Qdot (clone: 3B5, Invitrogen,
NY, US), CD3 APC H7 (clone: SK7), CD4 PerCP Cy 5.5 (clone:
L200), CD56 PE Cy 7 (clone: B159), CD14-fluorescein isothio-
cyanate (clone: M5E2) and CCR5 APC (clone: 2D7/CCR5, all
from BD, San Jose, CA, US). The samples were then washed with
2 mL of PBS, fixated using paraphormaldehyde (1%) and stored in
the fridge over night before analysis next morning. Staff analyzing
the samples were blinded to the FGS status.
Cells were acquired using an LSR II flow cytometer (BD) and
FACSDiva software (BD). The data was analyzed using FlowJo
software (Tree Star, Inc. version 9). Compensation and calibration
was performed daily using BD CaliBRITE beads. CD4 lympho-
cytes were defined and gated as CD3+CD4+ cells (Figure 3C),
while monocytes were defined and gated as
CD32CD562CD14+cells (Figure 3D). CCR5 positive cells on
monocytes, which express CD14, were defined and gated as
CD32CD562CD14+CCR5+ cells. Percentages of cells expressing
a given population were represented as a proportion of the parent
population. The proportion of cells in each subpopulation of cells
was compared in FGS positives and negatives. Back gating was
used to confirm the identity of the cell populations.
Statistical analyses
Statistical analyses were performed using IBM SPSS Statistics
version 20 (Armonk, NY, US). The Mann-Whitney U test was
used to compare the results from the flow cytometry in FGS+ and
FGS- and confidence intervals are given as inter quartile ranges
(IQR), as the data did not follow a normal distribution. To
Figure 2. Flowchart. Flowchart showing the inclusion of study participants (FGS= female genital schistosomiasis, CVL = cervicovaginal lavage).
doi:10.1371/journal.pone.0098593.g002
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compare results from samples collected before and after treatment
the Wilcoxon signed rank test was used. Pearson’s chi-square test
or Fisher’s exact test were used to compare the groups for STIs.
Samples yielding a minimum of 3,000 events after gating for CD3+
cells were included for further statistical analyses. A significance
level of 5% was used.
Results
We collected samples for flow cytometric analyses from 19
FGS+ and 25 FGS- women (Figure 2). Median age of the women
in this study was 18 years (range 15–23, Table 1). Of the 44
participants included, 30 (68%) met the criterion of a minimum of
3,000 CD3 positive events in the flow cytometry analysis in both
the mucosal and the blood sample. A median of 96,996 events
(live, CD3+ cells) in blood and 7,626 (live, CD3+ cells) in cervical
samples was analyzed.
A median of 4 STI analyses (range 0–5) were run in the patients
depending on the availability of specimens. FGS was significantly
associated with T. vaginalis (p = 0.007), but not with the other STIs
(Table 1). The FGS negative group did not differ from the main
study cohort when comparing STI prevalence (data not shown). In
the FGS+ group, 12 (63%) women had S. haematobium ova in urine
(Table 1). In the FGS+ women, there were similar levels of STIs in
the group with S. haematobium ova in urine (microscopy) and the
group with negative urines (p = 0.68). Of the FGS positive women,
14 out of the original 19 were seen 7–8 months after they had been
given anti-schistosomal treatment. At follow-up, none of the
Figure 3. Gating strategy. Figures showing the gating strategy for A) CD3+ B) CD32CD56+ C) CD3+CD4+ and CD3+CD8+ and D) CD32CD562CD14+.
doi:10.1371/journal.pone.0098593.g003
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treated cases had ova in urine (microscopy). One patient reported
to have received STI treatment between baseline and follow-up
and was therefore excluded from the analyses.
HIV target cells in blood samples
Women with FGS had a significantly higher proportion of
CD32CD562CD14+ cells than FGS- women in blood samples
(median 11.5% (IQR 4.7–19.9) vs. 2.2% (IQR 0.9–5.7) respec-
tively, p= 0.042; Figure 4A), whereas there was no significant
difference for CCR5 expression on CD14+ cells (p = 0.89; data not
shown). CD4+ T-cells expressing CCR5 were more frequent in
FGS positives than negatives (median 4.7% (IQR 1.7–8.1) vs.
1.5% (IQR 0.6–3.4) respectively, p = 0.018; Figure 4B). However,
the proportion of CD3+CD4+ T-cells was not significantly different
in FGS negatives and positives (median 54% and 51% respec-
tively, p = 0.86; data not shown).
HIV target cells in genital samples
In cervical cytobrush derived cells, the proportion of
CD32CD562CD14+ monocytes was not significantly different in
FGS negatives and positives (median 1.13 in both groups, p = 0.62;
data not shown). The CCR5 expression on CD14+ cells was higher
in the FGS positive group than the FGS negative group (30.3%
(IQR 18.6–47.2) vs. 11.6% (IQR 6.4–26.4) respectively, p = 0.036;
Figure 4C). There was no significant difference in CD3+CD4+ T-
cells in FGS+ individuals compared to FGS- individuals in the
genital samples (median 16.6 (IQR 4.7–25.5) vs. 31.1 (IQR 7.0–
47.9) respectively, p = 0.13; Figure 4D). No difference was found
when comparing CD4+ T-cells expressing CCR5 in FGS+ and
FGS- women (p = 0.29; data not shown).
Effect of praziquantel treatment on HIV target cells in
blood
In FGS+ women treated with praziquantel, the frequency of
cells in blood expressing CD14 (CD32CD562CD14+) was
significantly lower after treatment (pre-treatment median 17.0%
(IQR 3.9–20.6) compared to post-treatment median 1.11% (IQR
0.7–6.2), p = 0.043; Figure 5A). The level of CCR5 expression on
CD4+ cells decreased significantly after treatment (median 3.4%
(IQR 1.8–7.2) vs. 0.5% (IQR 0.4–1.8) respectively, p = 0.036;
Figure 5B). However, the proportion of
CD32CD562CD14+CCR5+ cells did not decrease significantly
(p = 0.23; data not shown). The median percentage of CD4+ T-
cells in blood was unchanged after treatment (51% before and
56% after treatment, p= 0.40; data not shown).
Effect of praziquantel treatment on HIV target cells in
genital samples
After treatment with praziquantel, the frequency of cells
expressing CD14 in genital samples was significantly lower than
before treatment (median 1.5% (IQR 0.8–3.6) vs. 1.0% (IQR 0.3–
1.6) respectively, p= 0.043; data not shown). For CD4+ T-cells, the
proportion was not significantly changed after treatment. The
proportion of monocytes and CD4+ cells expressing CCR5
decreased significantly post-treatment (median 34.4% (IQR
16.0–51.1) before vs. 7.0% (IQR 3.1–10.7) after treatment,
p = 0.043; Figure 5C and pre-treatment median 42.4% (IQR
17.6–56.3) vs. post-treatment median 5.6% (IQR 2.2–33.1),
p = 0.025; Figure 5D).
STI prevalence
T. vaginalis infection was associated with FGS (Table 1), but not
associated with any of the genital cell parameters and multivariate
analysis was therefore not performed. Thirty samples were
available for Chlamydia trachomatis analysis and this was associated
with CD4+ cells expressing CCR5 in cervical samples (p = 0.001).
The other STIs were not associated with any of the studied
parameters. When all STIs were added together, CD4+ cells
expressing CCR5 in blood was associated with having at least one
STI (p= 0.014), the other studied parameters were not signifi-
cantly associated.
Discussion
In this study of young women, we found that genital
schistosomiasis was associated with significantly higher frequencies
of CD14+ cells and higher frequencies of CD4+ cells expressing
CCR5 in blood. After anti-schistosomal treatment, we found that
Table 1. Characteristics of study participants by female genital schistosomiasis (FGS) status.
Variable FGS positive (n=19)a FGS negative (n =25)a pb
n (%) n (%)
Median age at baseline 18 17 0.030c
Schistosome ova in urine microscopyd 12 (63%) 0 (0%)
Schistosoma PCR positive in urined 12 (63%) 0/20
Schistosoma PCR positive in vaginal lavaged,e 5 (26%) 0/20
Trichomonas vaginalis 8 (42%) 1/21 (5%) 0.007
Herpes simplex virus 1 (5%) 0/20 (0%) 0.490
Neisseria gonorrhoea 3/13 (23%) 0/17 (0%) 0.070
Chlamydia trachomatis 4/13 (31%) 2/17 (12%) 0.360
Treponema pallidum 0 (0%) 2/9 (22%) 0.095
Injectable contraceptive 7 (28%) 6 (32%) 0.800
aAnalysis done on all if not stated otherwise.
bPearson’s chi-square or Fisher’s exact test.
cMann-Whitney U test.
dNot compared due to inclusion criteria of the negative group.
eThe pathology in female genital schistosomiasis is also due to dead, calcified ova. PCR may therefore be negative.
doi:10.1371/journal.pone.0098593.t001
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the CD14+ cell population had decreased significantly in both the
genital and blood compartments. Also the level of monocytes and
CD4+ T-cells expressing CCR5 decreased in cervical cytobrush
samples post treatment as well as the proportion of CD4+CCR5+
cells in blood.
Macrophages and CD4+ T-cells expressing the HIV co-receptor
CCR5 are susceptible to HIV infection [7]. Circulating monocytes
migrate to the tissues where they develop into various macrophage
subpopulations [6]. Mononuclear leukocytes are interspersed in
the mucosal columnar epithelium lining the endocervical channel
where they may be captured by using an endocervical cytobrush
[31–33,35]. Vaginal macrophages are monocyte-like and express
CD14 [7,8,36]. Since co-expression of CD14 and CD56 can
occur, monocytes were defined as CD32CD562CD14+ cells [37].
Helminthic infections are known to result in a Th2-dominated
immune response and S. mansoni induce alternatively activated
macrophages that contribute to different functions, such as fibrosis,
depending on the stage of the infection [38–40].
Women with primary or secondary syphilis, or Herpes simplex
virus (HSV) type-1 or -2 infections, have been shown to have
increased numbers of CD14 positive cells expressing CCR5 in
biopsies obtained from lesions. Patients with syphilis also had
increased co-receptor expression on monocytes from non-ulcerat-
ed tissue [41]. HSV-2 was associated with an increased number of
activated T-cells in the genital tract [42].
Histopathological studies have shown that schistosome ova are
surrounded by plasma cells, lymphocytes, eosinophil granulocytes
and macrophages [20,43]. A previous study reported high levels of
CD4+ T-cells around calcified ova typical of chronic infection
[20]. As our study found an apparent lack of effect of treatment on
CD4+ T-cells in the genital compartment, this may indicate that
there is a long-term, possibly refractory effect of schistosomal
infection. The included women may already have chronic lesions if
they contracted the infection at a young age. The density of
macrophages, however, was higher around viable S. haematobium
ova [20] and after treatment we found that the frequency
decreased indicating that the presence of genital macrophages
may be of a transient nature.
In vitro studies on peripheral blood mononuclear cells from
patients with current parasitic infection indicate that their cells are
more susceptible to HIV infection [44,45]. A systemic effect of
schistosomiasis was also described in individuals infected with S.
mansoni who expressed a higher, but not statistically significant,
density of the CCR5 receptor on CD4+ T-cells and monocytes in
blood which then decreased after anti-schistosomal treatment [46].
The finding of higher levels of CCR5 expression in CD4+ T-cells is
in accordance with our study and we also found a decrease in
CCR5 expression on these cells after anti-schistosomal treatment.
However, comparing schistosome infected and uninfected indi-
viduals, we did not see a higher CCR5 expression in monocytes in
Figure 4. Comparison of FGS+ and FGS2. Figures comparing the FGS positive (genital sandy patches) and negative (no genital sandy patches,
negative Schistosoma PCR in cervicovaginal lavage/urine and negative urine microscopy for ova). Figures show blood (A–B) and cervical samples (C–
D).
doi:10.1371/journal.pone.0098593.g004
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blood. The proportion of cells expressing CCR5, as well as the
density of receptors on each cell, are likely to influence HIV
susceptibility in vivo [47–49].
Dendritic cells are also involved in HIV transmission, possibly
both by direct and indirect transmission of the virus, and may
express CCR5 [50,51]. As we did not include a marker for this cell
population in our panel, we could not investigate these cells.
A crucial point is whether the cells captured by the cytobrush
method are really representative for the distribution of cells deeper
in the mucosa where the immunological processes take place.
Another limitation to our study was the fact that samples were
analyzed in two batches separated by approximately 8 months.
Even though the procedures were standardized, it is possible that
processing and analysis of the samples varied. We were not able to
follow up any negative cases, however baseline samples of
negatives were collected at both time points. We also noted that
a higher number of cervical cells were found in the second round
even though the same physicians collected the samples. Further,
we had a limited sample size that could cause type 2 errors. We
chose to use a significance level of 0.05 due to our small sample
size, but because multiple parameters were tested, it is possible that
some of these findings could represent false-positive results. The
study should therefore be repeated in a larger sample of women.
With a larger sample size, multivariate analysis would also have
been possible.
The negative controls are from an area endemic for schistoso-
miasis and may have been exposed to the parasite. However, none
of them were found to have current genital lesions. The risk of
HIV infection could therefore be different for the FGS positive
cases. Many contract urogenital schistosomiasis during childhood
and are therefore likely to have a chronic infection, but FGS
positive women may represent various stages of the disease [27].
No suitable diagnostic test is yet available for FGS [18]. Antibody
tests are of limited value in endemic areas since they can not
accurately differentiate between current or past disease [52] and
antigen tests in blood and urine are non-specific to the site of
pathology. Grainy sandy patches have been described as
pathognomonic to FGS [53]. It has been indicated that genital
lesions, once established, become chronic [26]. However, we
cannot preclude that some negative cases have had urogenital
schistosomiasis including healed genital lesions. If the negative
controls had been exposed to S. haematobium, the impact of
schistosomiasis infection on HIV target cells may be underesti-
mated.
It has been suggested that mucosal target cell availability in the
HIV negative susceptible individual may be an important factor in
transmission [12,54]. Also a higher level of CCR5 expression
might increase the susceptibility to HIV infection [55]. Recruit-
ment of HIV susceptible cells to the female genital mucosa may
increase the risk of contracting the disease and could alter the
progression of the infection. In addition to damaging the mucosal
Figure 5. Effect of praziquantel treatment. Figures comparing FGS positive individuals in blood (A–B) and cervical samples (C–D) before and
after praziquantel (40 mg/kg) treatment.
doi:10.1371/journal.pone.0098593.g005
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epithelial barrier, FGS may increase the HIV target cell
population both systemically and in the mucosal compartment.
Our finding that anti-schistosomal treatment decreases the fraction
of HIV susceptible CD14+ cells and the expression of the HIV co-
receptor CCR5 indicates that anti-schistosomal treatment may
become an additional tool in fighting the HIV epidemic.
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